Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized contr
Background and aim: Vasoplegic syndrome (VS) is a frequent complication following cardiopulmonary bypass (CPB) requiring escalating dose of vasopressor support. The guanylate cyclase inhibitor methylene blue (MB) could be an attractive alternative treatment in such cases. This study examines the eff...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2016-07-01
|
| Series: | Egyptian Journal of Anaesthesia |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1110184916300290 |
| _version_ | 1818456657100800000 |
|---|---|
| author | Raafat Abdelazim Dina Salah Heba A. Labib Ashraf A. El Midany |
| author_facet | Raafat Abdelazim Dina Salah Heba A. Labib Ashraf A. El Midany |
| author_sort | Raafat Abdelazim |
| collection | DOAJ |
| description | Background and aim: Vasoplegic syndrome (VS) is a frequent complication following cardiopulmonary bypass (CPB) requiring escalating dose of vasopressor support. The guanylate cyclase inhibitor methylene blue (MB) could be an attractive alternative treatment in such cases. This study examines the efficacy and safety of using MB compared to the commonly used norepinephrine in VS in pediatric population following CPB.
Methods: Forty patients of pediatric age group who developed VS following CPB for elective corrective cardiac surgeries received 0.5 μg/kg/min norepinephrine intravenous infusion for 5 min without improvement (Time 1). Patients were randomly assigned to two equal groups. Group MB received 1.5 mg/kg methylene blue by intravenous infusion over 20 min. Group N did not receive MB. Norepinephrine infusion was continued in both groups and titrated according to the response of patients with a maximum dose of 2 μg/kg/min (Time 2). Heart rate, mean arterial pressure (MAP), central venous pressure (CVP), cardiac output (CO), cardiac index (CI), mean pulmonary artery pressure (MPAP), systemic vascular resistance (SVR) and systemic vascular resistance index (SVRI) were calculated in both groups. Side effects related to the study drug were recorded.
Results: Time 2 values of norepinephrine dose were significantly lower in MB group compared to N group. Time 2 values of MAP were significantly higher in MB group compared to N group with a significant decrease in HR in MB group compared to N group. No change in the rhythm was detected in the two groups. Time 2 values of CVP were higher in MB group compared to N group. Time 2 values of CO and CI were significantly lower in MB group compared to N group and SVR and SVRI were significantly higher in MB group compared to N group. Time 2 values of MPAP were comparable in both groups and showed no significant change. No side effects from using MB were recorded as pulmonary edema and respiratory distress.
Conclusion: In this study, MB showed superior efficacy and safety in managing VS in pediatrics following CPB compared to the conventionally used norepinephrine. |
| first_indexed | 2024-12-14T22:30:09Z |
| format | Article |
| id | doaj.art-0de8ec483ac64ca7bad859bf0a0d68b4 |
| institution | Directory Open Access Journal |
| issn | 1110-1849 |
| language | English |
| last_indexed | 2024-12-14T22:30:09Z |
| publishDate | 2016-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Egyptian Journal of Anaesthesia |
| spelling | doaj.art-0de8ec483ac64ca7bad859bf0a0d68b42022-12-21T22:45:15ZengTaylor & Francis GroupEgyptian Journal of Anaesthesia1110-18492016-07-0132326927510.1016/j.egja.2016.05.001Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized contrRaafat Abdelazim0Dina Salah1Heba A. Labib2Ashraf A. El Midany3Department of Anesthesiology, Intensive Care, and Pain Management, Faculty of Medicine, Ain Shams University, EgyptDepartment of Anesthesiology, Intensive Care, and Pain Management, Faculty of Medicine, Ain Shams University, EgyptDepartment of Anesthesiology, Intensive Care, and Pain Management, Faculty of Medicine, Ain Shams University, EgyptDepartment of Cardiothoracic Surgery, Faculty of Medicine, Ain Shams University, EgyptBackground and aim: Vasoplegic syndrome (VS) is a frequent complication following cardiopulmonary bypass (CPB) requiring escalating dose of vasopressor support. The guanylate cyclase inhibitor methylene blue (MB) could be an attractive alternative treatment in such cases. This study examines the efficacy and safety of using MB compared to the commonly used norepinephrine in VS in pediatric population following CPB. Methods: Forty patients of pediatric age group who developed VS following CPB for elective corrective cardiac surgeries received 0.5 μg/kg/min norepinephrine intravenous infusion for 5 min without improvement (Time 1). Patients were randomly assigned to two equal groups. Group MB received 1.5 mg/kg methylene blue by intravenous infusion over 20 min. Group N did not receive MB. Norepinephrine infusion was continued in both groups and titrated according to the response of patients with a maximum dose of 2 μg/kg/min (Time 2). Heart rate, mean arterial pressure (MAP), central venous pressure (CVP), cardiac output (CO), cardiac index (CI), mean pulmonary artery pressure (MPAP), systemic vascular resistance (SVR) and systemic vascular resistance index (SVRI) were calculated in both groups. Side effects related to the study drug were recorded. Results: Time 2 values of norepinephrine dose were significantly lower in MB group compared to N group. Time 2 values of MAP were significantly higher in MB group compared to N group with a significant decrease in HR in MB group compared to N group. No change in the rhythm was detected in the two groups. Time 2 values of CVP were higher in MB group compared to N group. Time 2 values of CO and CI were significantly lower in MB group compared to N group and SVR and SVRI were significantly higher in MB group compared to N group. Time 2 values of MPAP were comparable in both groups and showed no significant change. No side effects from using MB were recorded as pulmonary edema and respiratory distress. Conclusion: In this study, MB showed superior efficacy and safety in managing VS in pediatrics following CPB compared to the conventionally used norepinephrine.http://www.sciencedirect.com/science/article/pii/S1110184916300290Methylene blueVasoplegic syndrome |
| spellingShingle | Raafat Abdelazim Dina Salah Heba A. Labib Ashraf A. El Midany Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized contr Egyptian Journal of Anaesthesia Methylene blue Vasoplegic syndrome |
| title | Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized contr |
| title_full | Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized contr |
| title_fullStr | Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized contr |
| title_full_unstemmed | Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized contr |
| title_short | Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized contr |
| title_sort | methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass a randomized contr |
| topic | Methylene blue Vasoplegic syndrome |
| url | http://www.sciencedirect.com/science/article/pii/S1110184916300290 |
| work_keys_str_mv | AT raafatabdelazim methylenebluecomparedtonorepinephrineinthemanagementofvasoplegicsyndromeinpediatricpatientsaftercardiopulmonarybypassarandomizedcontr AT dinasalah methylenebluecomparedtonorepinephrineinthemanagementofvasoplegicsyndromeinpediatricpatientsaftercardiopulmonarybypassarandomizedcontr AT hebaalabib methylenebluecomparedtonorepinephrineinthemanagementofvasoplegicsyndromeinpediatricpatientsaftercardiopulmonarybypassarandomizedcontr AT ashrafaelmidany methylenebluecomparedtonorepinephrineinthemanagementofvasoplegicsyndromeinpediatricpatientsaftercardiopulmonarybypassarandomizedcontr |